NOT FDA-APPROVED

IGF-1 LR3 (Long Arg3 IGF-1)

A modified version of insulin-like growth factor 1, engineered to dodge the binding proteins that normally clear it. Longer half-life, more bioavailable, more bodybuilder-popular, and more theoretically concerning on tumor biology than native IGF-1.

The 30-second read

IGF-1 LR3 (Long Arg3 IGF-1) is a modified version of the body's natural IGF-1, with two changes: a 13-amino-acid N-terminal extension and an arginine substitution at position 3. Those changes mean the peptide doesn't bind the IGF binding proteins (IGFBPs) that normally clear IGF-1 from the bloodstream, so its half-life jumps from minutes to roughly 20 hours, and a much larger fraction stays free and bioavailable. Native IGF-1 (Increlex) is FDA-approved for severe primary IGF-1 deficiency in pediatric patients. IGF-1 LR3 is not, it's a research peptide, used primarily in bodybuilding circles for muscle hypertrophy, with theoretical cancer concerns that are real and unresolved.

Why this peptide is on people's radar

IGF-1 is a hormone your liver makes in response to growth hormone, it's the downstream signal that drives most of GH's anabolic effects on tissues. Native IGF-1 has been the active ingredient of Increlex (mecasermin), an FDA-approved drug for children with severe primary IGF-1 deficiency. The clinical case for IGF-1 itself is real and well-defined: in kids who can't make their own, replacing it produces meaningful growth and metabolic benefit.

IGF-1 LR3 takes that base molecule and engineers around its main pharmacological problem: native IGF-1 has a plasma half-life of about 10 to 12 minutes because it gets bound up by IGF binding proteins (IGFBPs) almost immediately. The two changes in LR3, an N-terminal extension and an Arg substitution at position 3, drastically reduce IGFBP binding. The result is a peptide with a half-life around 20 hours that stays free and bioavailable to receptors much longer than the native molecule would.

That pharmacology made IGF-1 LR3 attractive in two communities: bodybuilding (for site-injection muscle hypertrophy and systemic anabolic effects) and research (as a tool for studying IGF-1-receptor biology without the IGFBP-dynamics confounds). Neither use is FDA-approved. The bodybuilding context is where you encounter LR3 in research-peptide channels.

What's worth knowing up front: IGF-1's natural role in the body includes promoting cell growth and division, and that's also part of why it has theoretical implications for cancer biology. Sustained elevation of free, bioavailable IGF-1, which is exactly what LR3 produces, is a more aggressive intervention than transient native-IGF-1 elevation, and the long-term safety data needed to characterize that risk in healthy adults using LR3 doesn't exist.

What people are usually trying to do with it

People exploring IGF-1 LR3 are usually focused on:

  • Muscle hypertrophy and lean-mass gain
  • Site-specific injection for targeted muscle growth (an older bodybuilding practice)
  • Recovery support after intense training
  • An anabolic option that bypasses the need to elevate GH first
  • A more potent IGF-1 analog than native IGF-1

What the science actually shows

Plain-English summary of what's actually documented:

Pharmacology, extended half-life and bioavailability

The pharmacological story is well-characterized. IGF-1 LR3's modifications successfully reduce IGFBP binding, extending half-life and increasing free IGF-1 exposure compared to native IGF-1. The peptide does what it's engineered to do biochemically.1

Anabolic effects in animal models

Animal studies report increased muscle hypertrophy, satellite cell activation, and improved lean-mass markers with IGF-1 LR3 administration. The anabolic biology is consistent with what's expected from sustained IGF-1-receptor activation.2

Native IGF-1 in clinical context (Increlex)

FDA-approved native IGF-1 (mecasermin / Increlex) has been shown to drive growth in children with severe primary IGF-1 deficiency. This validates the IGF-1 receptor pathway clinically, though Increlex is the native molecule, not LR3.3

IGF-1 and cancer biology

Higher endogenous IGF-1 levels have been associated with increased risk of certain cancers (prostate, breast, colorectal) in epidemiological studies. The relationship is complex and doesn't translate one-to-one to exogenous LR3 use, but it's the basis of the theoretical concerns.4

What hasn't been demonstrated

FDA approval of IGF-1 LR3 for any indication. Long-term safety data in healthy adults using LR3 for muscle hypertrophy. That site-injection produces meaningfully better localized hypertrophy than systemic injection (which is the basis of an older bodybuilding practice).

The honest read

What's solid:

The pharmacology of LR3, extended half-life via IGFBP-binding evasion, is well-characterized. The anabolic biology in animal models is real. Native IGF-1's clinical role (Increlex) validates the receptor pathway in defined clinical populations.

What's still unproven:

Long-term safety for healthy adults using LR3 for muscle hypertrophy. Whether the muscle-growth claims observed in animals translate to humans at typical research-community doses. Whether site-injection actually concentrates the effect locally or is essentially a systemic dose with extra steps.

What's a real concern:

The IGF-1 / cancer biology relationship is well-documented in epidemiology, higher endogenous IGF-1 is associated with elevated risk of several cancers. Sustained pharmacological elevation of free, bioavailable IGF-1, which is what LR3 produces, is theoretically more concerning than transient native-IGF-1 elevation. People with personal or strong family history of hormonally-influenced cancers (breast, prostate, colorectal) should treat the cancer-biology concern as a meaningful red flag rather than a distant theoretical issue.

What's hyped beyond the evidence:

"Direct anabolic, better than GH" framings. The trade-off in cancer-biology risk profile is a real one that often gets minimized in bodybuilding contexts. Site-injection localized-hypertrophy claims also outrun the evidence, the systemic dose still hits the body broadly. And anyone treating LR3 as functionally equivalent to FDA-approved Increlex is overstating LR3's clinical legitimacy.

Things to know if you're looking into it

  • Not the same as native IGF-1: the LR3 modifications create a more potent and longer-acting molecule than native IGF-1, with a different risk/benefit profile. Increlex (FDA-approved mecasermin) is native IGF-1, not LR3.
  • How it's used in research-community settings: typically a small subcutaneous injection, often timed post-workout. Some bodybuilding protocols use site-specific intramuscular injection.
  • Cancer-biology concern is real: personal or strong family history of breast, prostate, colorectal, or other hormonally-driven cancers is a meaningful contraindication, not a distant theoretical issue.
  • Hypoglycemia risk: IGF-1 (including LR3) can lower blood glucose. Monitor for hypoglycemia symptoms, especially with the first doses or with dose increases. Eating carbs around dosing is the standard mitigation.
  • Athlete bans: IGF-1 and its analogs are on the World Anti-Doping Agency banned list. Competitive athletes will test positive.
  • Regulatory status: not FDA-approved. Not currently on the FDA Category 2 list as of 2026.
  • Healthcare provider involvement: recommended, particularly given the cancer-biology and hypoglycemia considerations. Self-administered IGF-1 LR3 in research-peptide channels is a higher-risk choice than most peptides on this site.
  • Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.

Reconstitution & dose calculator

Not FDA-approved. Higher-stakes profile than most peptides on this site. The cancer-biology concern is real, not distant theoretical — sustained exogenous IGF-1 elevation has been linked epidemiologically to elevated risk of prostate, breast, and colorectal cancers. Personal or strong family history of hormonally-influenced cancers is a meaningful contraindication. Hypoglycemia is a real acute risk because IGF-1 has insulin-like effects on glucose. WADA banned.
Use 0.6% acetic acid water, not bacteriostatic water. IGF-1 LR3 is the one peptide in this catalog where reconstitution solvent meaningfully changes stability. The benzyl alcohol in BAC water degrades IGF-1 LR3 within 24–48 hours and the peptide aggregates at BAC water's near-neutral pH. In 0.6% acetic acid water, refrigerated, it stays stable for weeks to months. The standard mitigation for injection-site irritation from AA: back-load 4 parts BAC water to 1 part AA-reconstituted solution in the syringe immediately before injection — preserves vial stability while diluting the AA at the injection site.
Suggested start
20 mcg/day
Lower end of community range
Common range
20–60 mcg/day
Once daily, typically post-workout
Max community dose
100 mcg/day
Above this, cumulative-exposure concern grows
Cycle
4–6 wks max
Off-period at least equal — cumulative IGF-1 matters
mL
Defaults to 0.5 mg/mL (2 mL into the 1 mg vial). Use 0.6% acetic acid water, not BAC water — see the warning box above for the stability reasoning. The dilution choice (more dilute than the older 1 mg/mL standard) gives much better precision at IGF-1 LR3's small doses: 20–60 mcg lands at 4–12 syringe units instead of 2–6.
mcg
Subcutaneous injection, once daily, typically post-workout. Eat 30–50 g of fast-acting carbs within 30 min of every injection — this is the standard mitigation for IGF-1's insulin-like glucose effects, not optional. Never inject before sleep or while fasted — nighttime hypoglycemia is the most dangerous failure mode for this peptide.
Concentration
0.5 mg/mL
Per dose
0.04 mL
4 units on insulin syringe
Doses per vial
~50
~50 days (~7.1 weeks) of daily dosing

When to stay put vs. adjust

Stay put at 20 mcg daily for the first week to assess tolerance, particularly for hypoglycemia. The first doses are when blood-sugar drops are most likely. Always inject post-workout or with a meal, never before bed and never while fasted — sleep-onset hypoglycemia from IGF-1 is the genuinely dangerous failure mode and has been associated with serious adverse events. Eat 30–50 g of fast-acting carbs (juice, glucose tabs, dextrose, white rice) within 30 minutes of every injection. If you feel light-headed, shaky, sweaty, or unusually hungry within an hour of dosing, that's hypoglycemia and you need carbs immediately.

Consider stepping to 30–40 mcg daily only after at least one week at 20 mcg with no hypoglycemic episodes and clear tolerability. The 30–60 mcg range is where most of the community's anecdotal benefit reports sit. Going higher doesn't reliably produce proportionally better results — IGF-1 receptors aren't a linear "more is better" target, and the cumulative-exposure concern grows with both dose and duration.

Don't go above 100 mcg daily, and even at 60–100 mcg, you're exiting the well-trodden community range. The cancer-biology concern scales with total IGF-1 exposure (dose × duration), and pushing both up simultaneously is the worst version of the trade-off.

Cycle off at 4–6 weeks regardless of progress. Long-term continuous use of LR3 isn't characterized for safety in healthy adults, and the cumulative-IGF-1-exposure question is where the cancer concern lives. An off-period at least equal to the on-period (so 4 weeks on / 4 weeks off, minimum) is the conservative default. Some research-community protocols use a much shorter window — 50 mcg/day for 10 days, then 4 weeks off — specifically to keep cumulative IGF-1 exposure low. That short-pulse pattern is the more conservative choice if you're worried about the cancer-biology angle.

Watch for hypoglycemia first, then edema, joint discomfort, and any unusual lumps or swelling. The acute risk is blood sugar; the chronic risk pattern includes fluid retention and the possibility of accelerating any pre-existing tissue growth. People with personal or strong family history of breast, prostate, or colorectal cancer should treat this as a meaningful contraindication rather than a footnote.

Site-injection localized hypertrophy is more myth than evidence. Bodybuilding protocols sometimes inject LR3 directly into specific muscles claiming targeted growth. Some local effect at the injection site is plausible, but a substantial portion of the dose enters systemic circulation regardless of injection location — you're getting whole-body IGF-1 elevation either way, just with an extra step.

The honest read. IGF-1 LR3's pharmacology is well-characterized and the anabolic biology in animals is real. Native IGF-1 (Increlex / mecasermin) is FDA-approved for severe pediatric IGF-1 deficiency, which validates the receptor pathway in defined clinical populations. None of that translates to healthy adults using LR3 for muscle growth without addressing the cancer-biology concern, which sustained pharmacological elevation of free, bioavailable IGF-1 specifically activates. This is one of the higher-stakes peptides on the site. Anyone treating it as functionally equivalent to a GH secretagogue stack (CJC/Ipa) is missing that the risk profiles are genuinely different.

For educational and research purposes only. This is not medical advice. IGF-1 LR3 is not FDA-approved. The cancer-biology concern is real and warrants particular caution in anyone with personal or family history of hormonally-influenced cancers. IGF-1 is on the WADA banned list. Hypoglycemia is an acute risk requiring carb intake around dosing. Consult a licensed healthcare provider before any health decision.

What people often ask

How is IGF-1 LR3 different from regular IGF-1?

Two structural changes: a 13-amino-acid N-terminal extension and an arginine substitution at position 3. Both reduce binding to IGF binding proteins (IGFBPs). Result: native IGF-1 has a half-life of about 10–12 minutes, IGF-1 LR3 has a half-life around 20 hours. The LR3 form stays free and bioavailable longer.

Is IGF-1 LR3 the same as Increlex?

No. Increlex (mecasermin) is native, recombinant human IGF-1. FDA-approved for severe primary IGF-1 deficiency in pediatric patients. IGF-1 LR3 is the engineered LR3 variant, not FDA-approved, used in research and bodybuilding contexts. Different drugs, different regulatory status.

Does it actually grow muscle?

Animal data supports anabolic effects. Human evidence in healthy adults using LR3 for muscle hypertrophy is mostly anecdotal from bodybuilding contexts. Effect sizes vary widely.

What's the cancer concern?

Higher endogenous IGF-1 is associated with elevated risk of several cancers in epidemiology. Sustained pharmacological elevation of free, bioavailable IGF-1 (what LR3 produces) is theoretically more concerning than transient native-IGF-1 elevation. People with personal or strong family history of hormonally-driven cancers should consider this a meaningful contraindication.

Is it FDA-approved?

No. Not approved for any indication. Not currently on the FDA Category 2 list, but operating outside FDA drug oversight in research-peptide channels.

Can it cause hypoglycemia?

Yes. IGF-1 has insulin-like effects on glucose disposal and can lower blood sugar. Especially relevant for first-time users, with dose increases, or in fasted states. Eating carbs around dosing is the standard mitigation.

Does site-injection actually grow that muscle locally?

The bodybuilding theory is yes; the rigorous evidence is thin. Some local effect at the injection site is plausible, but a substantial portion of the dose still enters systemic circulation. Site-injection is more myth-soaked than evidence-based.

FDA and regulatory status

Status as of May 5, 2026: Not FDA-approved for any medical indication. Native IGF-1 (mecasermin / Increlex) is FDA-approved for severe primary IGF-1 deficiency in pediatric patients, but IGF-1 LR3 is a different molecule and is not FDA-approved. Not currently on the FDA Category 2 list. On the World Anti-Doping Agency Prohibited List. Status updates land here when they happen.

Want to go deeper? Mechanism, IGFBP biology, dosing, side-effect profile, and references.

Background

IGF-1 LR3 (Long Arginine 3 Insulin-like Growth Factor-1) is a modified recombinant analog of human IGF-1. Two structural modifications distinguish it from the native molecule: a 13-amino-acid N-terminal extension (the "Long" part) and substitution of arginine for glutamic acid at position 3 (the "Arg3" part). Both modifications reduce binding affinity to the IGF binding proteins (IGFBP-1 through IGFBP-6) that normally sequester native IGF-1 in the bloodstream.

Mechanism of action

IGF-1 receptor activation

LR3 binds the IGF-1 receptor (IGF1R) similarly to native IGF-1, triggering the same downstream PI3K-Akt-mTOR and MAPK signaling cascades that drive cell growth, protein synthesis, and metabolic effects.

IGFBP evasion

The N-terminal extension and Arg3 substitution dramatically reduce LR3's affinity for IGFBPs. Native IGF-1 is bound by IGFBPs almost immediately upon release, with only a small fraction free at any time. LR3 stays free and bioavailable, dramatically extending the receptor-exposure window.

Half-life

Plasma half-life is approximately 20 hours, compared with 10–12 minutes for native IGF-1.

Why this matters for risk

The same pharmacology that makes LR3 attractive (sustained free IGF-1 exposure) also makes it more biologically aggressive than native IGF-1. The IGFBP system is, in part, a buffer against excessive IGF-1 signaling. Bypassing it produces a different long-term receptor-activation pattern than the body normally experiences.

Commonly studied dosing protocols

These are not recommendations. Always consult a licensed healthcare provider before any clinical decision. IGF-1 LR3 carries real cancer-biology and hypoglycemia considerations.

Subcutaneous (research-community range): 20 to 60 mcg per day, typically once daily, often post-workout.

Site injection (older bodybuilding practice): intramuscular injection near specific muscles intended for hypertrophy. The localized-effect claim is more anecdotal than evidence-based.

Treatment duration: typical research-community cycles are 4 to 6 weeks. Long-term continuous use raises the cumulative IGF-1-exposure question, which is where the cancer-biology concern sits.

Side effects and safety profile

Reported in research-community use:

  • Hypoglycemia, symptoms including shakiness, sweating, lightheadedness, hunger; manageable with carbohydrate intake around dosing
  • Injection-site reactions (mild)
  • Mild fatigue or lethargy (uncommon)
  • Transient joint or muscle aches (uncommon)
  • Edema or fluid retention (uncommon, dose-dependent)

Serious theoretical concerns: the cancer-biology relationship is the most important consideration for chronic use, particularly in people with personal or strong family history of hormonally-influenced cancers. Acromegaly-like effects (organ enlargement, jaw growth) are also a theoretical concern with sustained high-dose IGF-1 elevation that hasn't been characterized in research-peptide LR3 use specifically.

References

  1. Tomas FM, Knowles SE, Owens PC, et al. (1993). "Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats." Biochem J, 282(Pt 1), 91–97. PubMed
  2. Conlon MA, Tomas FM, Owens PC, et al. (1995). "Long-R3-insulin-like growth factor-I (LR3IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig." J Endocrinol, 144(1), 91–98. PubMed
  3. U.S. Food and Drug Administration. "Increlex (mecasermin) Prescribing Information." FDA.gov
  4. Renehan AG, Zwahlen M, Minder C, et al. (2004). "Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis." The Lancet, 363(9418), 1346–1353. PubMed
  5. Adams GR, McCue SA. (1998). "Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats." J Appl Physiol, 84(5), 1716–1722. PubMed
For educational and research purposes only. This is not medical advice. IGF-1 LR3 is not FDA-approved. Carries real cancer-biology and hypoglycemia considerations that should be taken seriously. Personal or strong family history of hormonally-driven cancers is a meaningful contraindication. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.